Walid Elbast

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys

Thérèse Di Paolo, Laurent Grégoire, Dominik Feuerbach et al. · Parkinsonism & Related Disorders · 2014 · 42 citations

Medicine, Synaptic Transmission, Nicotine +11

Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity

Marie-Sophie Caubet, Walid Elbast, Marie-Claude Dubuc et al. · Journal of Pharmaceutical and Biomedical Analysis · 2002 · 35 citations

Energy Metabolism, Cyp1a2 Enzyme Activity, Urinary Caffeine Metabolites +12

Mapping the pharmaceutical design space by amorphous ionic liquid strategies

Johannes Wiest, Marco Saedtler, Anja Balk et al. · Journal of Controlled Release · 2017 · 35 citations

Materials Science, Solid-state Ionic, Medicinal Chemistry +13

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

Veit J. Erpenbeck, Eva Vets, Lien Gheyle et al. · Clinical Pharmacology in Drug Development · 2015 · 24 citations · Full text

Healthy Subjects, Pharmacotherapy, Experimental Pharmacology +17

European Bioanalysis Forum: Recommendation for Dealing with Internal Standard Variability

Stephen White, Neil Adcock, Walid Elbast et al. · Bioanalysis · 2014 · 23 citations

Environmental Monitoring, Engineering, Measurement +18